Portal de Periódicos da CAPES

Acute lymphoblastic leukaemia

2013; Elsevier BV; Volume: 381; Issue: 9881 Linguagem: Inglês

10.1016/s0140-6736(12)62187-4

1474-547X

Hiroto Inaba, Mel Greaves, Charles G. Mullighan,

Neuroblastoma Research and Treatments

Summary Acute lymphoblastic leukaemia occurs in both children and adults but its incidence peaks between 2 and 5 years of age. Causation is multifactorial and exogenous or endogenous exposures, genetic susceptibility, and chance have roles. Survival in paediatric acute lymphoblastic leukaemia has improved to roughly 90% in trials with risk stratification by biological features of leukaemic cells and response to treatment, treatment modification based on patients' pharmacodynamics and pharmacogenomics, and improved supportive care. However, innovative approaches are needed to further improve survival while reducing adverse effects. Prognosis remains poor in infants and adults. Genome-wide profiling of germline and leukaemic cell DNA has identified novel submicroscopic structural genetic changes and sequence mutations that contribute to leukaemogenesis, define new disease subtypes, affect responsiveness to treatment, and might provide novel prognostic markers and therapeutic targets for personalised medicine.